April 4, 2019
Novartis’ DPP-4 inhibitor/metformin combo EquMet (vildagliptin + metformin) became its best-selling drug in Japan in 2018 three years after its launch in November 2015, raking in sales of 25.1 billion yen on an NHI price basis, up 20% over the...read more